SCD and adenocarcinoma: The analysis revealed that 1925 lung cancer and 719 adenocarcinoma patients with low expression of SCD had longer overall survival (OS), progression-free survival (PFS), and post-progression survival (PPS) than the patients with high expression of SCD (Fig. 6D).